Mammalian cell tissue culture is critical to biomedical research and to the production of many blockbuster drugs. Animal-sourced sera provide the growth factors and cytokines that are essential for tissue culture. After an initial $1.5 million investment, TildenBio's photosynthetic platform is suited to producing biomedical proteins economically, simply, and at large scale. We have achieved expression levels of over 20% of total protein. TildenBio’s technology is simultaneously applicable to a number of markets, including the diagnostic market, edible vaccine market, industrial enzyme market, and possibly next-generation antibiotic markets. With an initial beachhead focused on producing low-cost growth factors and cytokines as replacements for animal-sourced tissue culture sera, TildenBio is searching for a CEO to lead the team into its next chapter.